Deoxynucleoside triphosphate (dNTP)

Deoxynucleoside triphosphates (dNTPs) are the essential building blocks required for the synthesis of DNA in all living organisms. They consist of four distinct molecules—dATP, dGTP, dCTP, and dTTP—which are utilized by DNA polymerases during replication and repair processes in both the nucleus and mitochondria (PMID: 21855346). The regulation of dNTP pools is a critical homeostatic process managed by enzymes such as ribonucleotide reductase (RNR) and the triphosphohydrolase SAMHD1; imbalances in these pools can lead to increased mutation rates, genomic instability, and cell death (PMID: 25635005). In therapeutic contexts, dNTP metabolism is a major target for antiviral and anticancer treatments. Many clinical drugs are nucleoside analogs that mimic dNTPs to inhibit viral or cellular polymerases, while others, such as hydroxyurea, target the biosynthetic pathways of dNTPs to arrest the growth of rapidly dividing malignant cells (PMID: 22561068). Furthermore, deficiencies in dNTP maintenance are linked to severe metabolic disorders, such as mitochondrial DNA depletion syndromes, highlighting their vital role in cellular health (PMID: 24336226).

Other names

Deoxyribonucleoside triphosphatedNTPsDNA precursorsDeoxynucleotidesDeoxyribonucleotide triphosphate

Drugs targeting dNTPs typically function as antimetabolites that act as competitive inhibitors of DNA polymerases or as chain terminators upon incorporation into the nascent DNA strand. Additionally, some agents inhibit upstream enzymes like ribonucleotide reductase (RNR) or thymidylate synthase to deplete the intracellular dNTP pools, thereby starving the cell of the precursors necessary for DNA synthesis and repair.